WebFeb 17, 2024 · Cytonics will initiate preclinical trials to investigate the ability of CYT-108 to inhibit lung inflammation (caused by Acute Respiratory Distress Syndrome, COVID-19, COPD, and more). CYT-108 may be a potent inhibitor of both the proteases and cytokines that underly inflammatory lung diseases. WebWe are currently pursuing pre-clinical trials for this pharmaceutical “recombinant” version of A2M, CYT-108. This synthetic drug has been engineered to function more effectively …
Cytonics Has Expressed and Purified an ... - Cytonics Corporation
WebAug 9, 2024 · Our goal is to develop CYT-108 through Phase 1 clinical trials by the end of 2024, then partner with a larger pharmaceutical company to conduct the Phase 2 study. … WebApr 25, 2024 · This means that as long as CYT-108 is chemically similar to the APIC formulation then it should be both safe and effective in humans. We have already shown that CYT-108 is 2-4x more effective than the standard of care in animal models, and anticipate a successful pre-clinical trial," said Joey Bose, President of Cytonics Corporation. chipping show fell race
COVID-19 - Cytonics Corporation
WebJun 9, 2024 · The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108 and raising capital for Phase 1 clinical trials ( invest.cytonics.com ). About... WebIf successful, CYT-108 will be the only approved therapy to treat the root cause of osteoarthritis. Why seek funding via the Regulation A+ route instead of Venture Capital? Regulation A+ is a unique capital raising method because it allows the public to participate in early-stage companies that have the potential to be disruptive. WebApr 10, 2024 · CYT-108 is a revolutionary biologic therapy for treating osteoarthritis. When injected into the afflicted joint, CYT-108 binds to cartilage-destroying enzyme... grapes and paints overland park